Romana Marko Masnikosa

Dr. Romana Marko Masnikosa

Institute of Nuclear Sciences, University of Belgrade, Belgrade, Beograd, Serbia
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in Coordination Chemistry Reviews
Verified
Journal Article
Closed access
ASAna Rilak Simović
Ana Rilak Simović
RMRomana Marko Masnikosa
Romana Marko Masnikosa
IBIoannis Bratsos
Ioannis Bratsos
EAEnzo Alessio
Enzo Alessio

31 August 2018 in Dalton Transactions
Verified
Journal Article
Closed access
PDF file
Snežana StojanovićSnežana Stojanović
Snežana Stojanović
IBIoannis Bratsos
Ioannis Bratsos
ASAndreas Scheurer
Andreas Scheurer
JKJana Korzekwa
Jana Korzekwa
RMRomana Marko Masnikosa
Romana Marko Masnikosa
ASAna Rilak Simović
Ana Rilak Simović
The complex [Au(H 2 L tBu )Cl]Cl 2 ( 1 ) induced perturbations of the cell cycle and led to apoptosis in human melanoma A375 cells.


Verified
Journal Article
Open access
PDF file
RMRomana Marko Masnikosa
Romana Marko Masnikosa
Zorica CvetkovićZorica Cvetković
Zorica Cvetković
DPDavid Piric
David Piric
Diffuse large B-cell lymphoma (DLBCL) is a malignancy of immense biological and clinical heterogeneity. Based on the transcriptomic or genomic approach, several different classification schemes have evolved over the years to subdivide DLBCL into clinically (prognostically) relevant subsets, but each leaves unclassified samples. Herein, we outline the DLBCL tumor biology behind the actual and potential drug targets and address the challenges and drawbacks coupled with their (potential) use. Therapeutic modalities are discussed, including small-molecule inhibitors, naked antibodies, antibody–drug conjugates, chimeric antigen receptors, bispecific antibodies and T-cell engagers, and immune checkpoint inhibitors. Candidate drugs explored in ongoing clinical trials are coupled with diverse toxicity issues and refractoriness to drugs. According to the literature on DLBCL, the promise for new therapeutic targets lies in epigenetic alterations, B-cell receptor and NF-κB pathways. Herein, we present putative targets hiding in lipid pathways, ferroptosis, and the gut microbiome that could be used in addition to immuno-chemotherapy to improve the general health status of DLBCL patients, thus increasing the chance of being cured. It may be time to devote more effort to exploring DLBCL metabolism to discover novel druggable targets. We also performed a bibliometric and knowledge-map analysis of the literature on DLBCL published from 2014–2023.

1 June 2014 in Mechanisms of Ageing and Development
Verified
Journal Article
Closed access
DRDragana Robajac
Dragana Robajac
RMRomana Marko Masnikosa
Romana Marko Masnikosa
VVValerie Vanhooren
Valerie Vanhooren
CLClaude Libert
Claude Libert
ŽMŽeljko Miković
Željko Miković
ONOlgica Nedic
Olgica Nedic

20 March 2000 in Clinica Chimica Acta
Verified
Journal Article
Closed access
JNJ.Anna Nikolić
J.Anna Nikolić
VTVera Todorović
Vera Todorović
MBMilena Božić
Milena Božić
LTLjubinka Tošić
Ljubinka Tošić
MBMirko Bulajić
Mirko Bulajić
RMRomana Marko Masnikosa
Romana Marko Masnikosa